UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )
Pharmion Corporation
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.001 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
71715B409
----------------------------------------------------------------------
(CUSIP Number)
Leo Kirby
667 Madison Avenue, 17th Floor
New York, NY 10065
(212) 339-5633
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
February 8, 2008
----------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box. |X|
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 (the "Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 7 Pages
SCHEDULE 13D
------------------- -----------------
CUSIP No. 71715B409 Page 2 of 7 Pages
------------------- -----------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Julian C. Baker
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) OR 2(e) |_|
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY --------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON 2,855,271
WITH --------------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
--------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,855,271
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,855,271
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See
Instructions) |_|
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.6%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
IN
--------------------------------------------------------------------------------
Page 2 of 7 Pages
SCHEDULE 13D
------------------- -----------------
CUSIP No. 71715B409 Page 3 of 7 Pages
------------------- -----------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Felix J. Baker
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) OR 2(e) |_|
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY --------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON 2,855,271
WITH --------------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
--------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,855,271
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,855,271
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See
Instructions) |_|
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.6%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
IN
--------------------------------------------------------------------------------
Page 3 of 7 Pages
Item 1. Security and Issuer.
This statement on Schedule 13D relates to the common stock, $.001
per share par value (the "Common Stock"), of Pharmion Corporation, (the
"Company"), whose principal executive offices are located at 2525 28th Street,
Suite 200, Boulder, Colorado 80301.
Item 2. Identity and Background.
This statement is being filed by Julian C. Baker and Felix J. Baker
(each, a "Reporting Person"), each of whom is a United States citizen. Set forth
below is certain information with respect to each Reporting Person:
Name Business Address Present Principal Occupation
---- ---------------- ----------------------------
Julian C. Baker 667 Madison Avenue 17th Floor Managing Member, Baker Bros. Advisors,
New York, NY 10065 LLC (an entity engaged in investment
activities)
Felix J. Baker 667 Madison Avenue 17th Floor Managing Member, Baker Bros. Advisors,
New York, NY 10065 LLC (an entity engaged in investment
activities)
During the last five years, none of the Reporting Persons has been
convicted in any criminal proceeding (excluding traffic violations or similar
misdemeanors) or has been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction resulting in his being subject to
a judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws, or finding
any violations with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
The funds used to purchase the shares of Common Stock reported in
Item 5 below were provided from the available working capital of the entities
there indicated.
Item 4. Purpose of Transaction.
The entities referred to in Item 5 below acquired the shares of
Common Stock set forth therein solely for investment in the ordinary course of
business and not with the purpose nor with the effect of changing or influencing
the control of the Company or as a participant in any transaction having that
purpose or effect.
As a part of their ongoing review of the investment positions of
these entities, the Reporting Persons from time to time evaluate the Company's
business, operations, financial condition and prospects and, depending upon
their continuing assessments of pertinent factors, including other business
investment opportunities, economic conditions, market conditions, actions and
public statements of members of the Board of Directors and management of the
Company, the availability and nature of opportunities to dispose of shares in
Page 4 of 7 Pages
the Company and other plans and requirements of the particular entities, may
increase or decrease the entities' holdings of the Company's Common Stock or
communicate with members of the Board of Directors or management of the Company
or other shareholders of the Company regarding any of the foregoing matters. The
Reporting Persons may also change their present intentions stated above.
At the present time the Reporting Persons do not have any plans or
proposals with respect to any extraordinary corporate transaction involving the
Company or any sale of its assets or any change in its Board of Directors,
management, capitalization, dividend strategy, charter or by-laws, or any other
change in its business or corporate structure or with respect to the delisting
or deregistration of any of its securities including, without limitation, those
matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
Item 5. Interest in Securities of the Issuer.
Set forth below is the aggregate number of shares of Common Stock
held, including shares that maybe acquired upon the exercise of Options, as of
the date hereof by each of the following, together with the percentage of
outstanding shares of Common Stock that such number represents based upon
37,392,423 shares outstanding as reported in the Company's Form 10Q filed on
November 9, 2007. Such percentage figures are calculated on the basis that the
Options owned by the Reporting Persons are deemed exercised for shares of Common
Stock but other outstanding Options are not deemed exercised.
Number of Percent of Class
Name Shares Outstanding
---------------------------------- --------- ----------------
Baker Bros. Investments II, L.P. 5,254 0.0%
Baker Biotech Fund I, L.P 721,089 1.9%
Baker Brothers Life Sciences, L.P. 2,061,551 5.5%
14159, L.P. 65,752 0.2%
Baker/ Tisch Investments, L.P. 1,625 0.0%
---------------------------------- --------- ----
Total 2,855,271 7.6%
By virtue of their ownership of entities that have the power to
control the investment decisions of the limited partnerships listed in the table
above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial
owners of shares owned by such entities and may be deemed to have shared power
to vote or direct the vote of and shared power to dispose or direct the
disposition of such securities.
The following transactions in Common Stock were effected by the
entities noted below during the sixty days preceding the filing of this
statement. None of the reporting Persons has effected any other transactions in
Common Stock during this period.
Page 5 of 7 Pages
-----------------------------------------------------------------------------------------------
Name Date Number of Shares Transaction Price/
Share
-----------------------------------------------------------------------------------------------
Baker Brothers Investments II, L.P. 12/20/2007 7 Purchase 58.7472
-----------------------------------------------------------------------------------------------
Baker Biotech Fund I, L.P. 12/20/2007 981 Purchase 58.7472
-----------------------------------------------------------------------------------------------
Baker Brothers Life Sciences, L.P. 12/20/2007 2,482 Purchase 58.7472
-----------------------------------------------------------------------------------------------
14159, L.P. 12/20/2007 78 Purchase 58.7472
-----------------------------------------------------------------------------------------------
Baker/ Tisch Investments, L.P. 12/20/2007 52 Purchase 58.7472
-----------------------------------------------------------------------------------------------
Baker Brothers Investments II, L.P. 1/23/2008 73 Sale 66.2475
-----------------------------------------------------------------------------------------------
Baker Biotech Fund I, L.P. 1/23/2008 10,263 Sale 66.2475
-----------------------------------------------------------------------------------------------
Baker Brothers Life Sciences, L.P. 1/23/2008 28,505 Sale 66.2475
-----------------------------------------------------------------------------------------------
14159, L.P. 1/23/2008 908 Sale 66.2475
-----------------------------------------------------------------------------------------------
Baker/ Tisch Investments, L.P. 1/23/2008 24 Sale 66.2475
-----------------------------------------------------------------------------------------------
Item 7. Material to Be Filed as Exhibits.
Exhibit 1. Agreement regarding the joint filing of this statement.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and
correct.
February 8, 2008
By: /s/ Julian C. Baker
------------------------------
Julian C. Baker
By: /s/ Felix J. Baker
-------------------------------
Felix J. Baker
Page 6 of 7 Pages
EXHIBIT 1
AGREEMENT
In accordance with Rule 13d-1(k)(1) under the Securities Exchange
Act of 1934, as amended, the undersigned hereby agree that this Statement on
Schedule 13D relating to the Common Stock, $0.001 par value, of Pharmion
Corporation is being filed with the Securities and Exchange Commission on behalf
of each of them.
February 8, 2008
By: /s/ Julian C. Baker
------------------------------
Julian C. Baker
By: /s/ Felix J. Baker
------------------------------
Felix J. Baker
Page 7 of 7 Pages